Pancreatic Cancer Research

ResearcherOsaka International Cancer InstituteActive in the last 2 years

Ryoji Takada

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-6568-8091; OpenAlex author ID A5043761394. Sources: OpenAlex.

Their work

Papers
31 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
58
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: 1 paper · 2017: none · 2018: 2 papers · 2019: none · 2020: 3 papers · 2021: 3 papers · 2022: 6 papers · 2023: 4 papers · 2024: 3 papers · 2025: 3 papers · 2026: 5 papers

Papers 31

  1. Genetic and Clinical Characteristics of Patients With Tumor Mutation Burden-High Unresectable Pancreatic Cancer and the Efficacy of Pembrolizumab Treatment. Co-author DOI 10.1002/cnr2.70492↗
  2. Prospective Phase II Trial of Biweekly Gemcitabine Plus Nab-Paclitaxel as First-Line Therapy in Patients Aged 75 Years and Older With Unresectable Pancreatic C… Co-author DOI 10.1002/cnr2.70691↗
  3. Effects of Pancreatic Duct Stenting on Nutrition and Pancreatic Function in Unresectable Pancreatic Cancer: A Pilot Study. Co-author DOI 10.1002/jgh3.70358↗
  4. Association between response to gemcitabine-based neoadjuvant therapy and efficacy of gemcitabine plus nab-paclitaxel for recurrent pancreatic ductal adenocarc… Co-author DOI 10.1007/s10147-026-03071-6↗
  5. Clinical significance of non-invasive in vitro drug sensitivity profiling using pancreatic cancer organoids derived from saline flushes collected during routin… Co-author DOI 10.1007/s12094-025-04111-9↗
  6. Clinical Outcome and Safety of Triweekly Modified FOLFIRINOX Therapy in Patients with Advanced Pancreatic Cancer. Co-author DOI 10.1007/s12029-025-01309-6↗
  7. Impact of zinc deficiency on the prognosis of unresectable pancreatic cancer. Co-author DOI 10.1016/j.pan.2025.05.007↗
  8. The effect of neoadjuvant chemoradiation therapy in resectable pancreatic cancer was independent of intratumoral vascularization. Co-author DOI 10.1186/s12876-025-04108-2↗
  9. Zinc supplementation for dysgeusia in patients with unresectable pancreatic cancer. Co-author DOI 10.1007/s10147-024-02544-w↗
  10. Mcl-1 expression is a predictive marker of response to gemcitabine plus nab-paclitaxel for metastatic pancreatic cancer. Co-author DOI 10.1038/s41598-024-73020-8↗
  11. Clinical significance of germline breast cancer susceptibility gene (gBRCA) testing and olaparib as maintenance therapy for patients with pancreatic cancer. Co-author DOI 10.1186/s12885-024-12722-8↗
  12. Hospital volume and prognosis of patients with metastatic pancreatic cancer: A study using the Osaka Cancer Registry. Co-author DOI 10.1007/s00432-023-04966-x↗
  13. Effect of systemic inflammatory response on induction chemotherapy followed by chemoradiotherapy for locally advanced pancreatic cancer: an exploratory subgrou… Co-author DOI 10.1093/jjco/hyad044↗
  14. Parallel administration of nanoliposomal irinotecan and levo-leucovorin for pancreatic cancer. Co-author DOI 10.1186/s12885-023-11205-6↗
  15. Utility of Comprehensive Genomic Profiling Tests for Patients with Incurable Pancreatic Cancer in Clinical Practice. Co-author DOI 10.3390/cancers15030970↗
  16. Chemotherapy effectiveness and age-group analysis of older adult patients with metastatic pancreatic cancer: A Japanese cancer registry cohort study. Co-author DOI 10.1016/j.jgo.2022.07.010↗
  17. Establishment of organoids using residual samples from saline flushes during endoscopic ultrasound-guided fine-needle aspiration in patients with pancreatic ca… Co-author DOI 10.1055/a-1713-3404↗
  18. Refractory Lower Limb Edema Resolved by Endovascular Stent Placement for Inferior Vena Cava Stenosis in Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000002152↗
  19. Early detection of venous thromboembolism after the initiation of chemotherapy predicts a poor prognosis in patients with unresectable metastatic pancreatic ca… Co-author DOI 10.1371/journal.pone.0264653↗
  20. New Screening System Using Forward-Viewing Radial Endoscopic Ultrasound and Magnetic Resonance Imaging for High-Risk Individuals With Familial History of Pancr… Co-author DOI 10.3389/fmed.2022.928182↗
  21. 5-Fluorouracil/L-Leucovorin Plus Oxaliplatin (FOLFOX) Regimen as Salvage Chemotherapy for Patients with Unresectable Pancreatic Cancer Receiving Gemcitabine an… Co-author DOI 10.3390/curroncol29040216↗
  22. Efficacy and safety of modified fluorouracil/leucovorin plus irinotecan and oxaliplatin (mFOLFIRINOX) compared with S-1 as second-line chemotherapy in metastat… Co-author DOI 10.1002/jgh3.12555↗
  23. Predictive Factors for Pancreatic Cancer and Its Early Detection Using Special Pancreatic Ultrasonography in High-Risk Individuals. Co-author DOI 10.3390/cancers13030502↗
  24. The Survival Benefit of Chemoradiotherapy following Induction Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Unresectable Locally Advanced Pancreatic Ca… Co-author DOI 10.3390/cancers13184733↗
  25. Efficacy of Larger-Diameter Plastic Stent Placement for Preoperative Biliary Drainage in Patients Receiving Neoadjuvant Chemoradiation for Pancreatic Cancer. First author DOI 10.1097/mpa.0000000000001509↗
  26. Clinical Utility of Pancreatic Cancer Circulating Tumor DNA in Predicting Disease Progression, Prognosis, and Response to Chemotherapy. Co-author DOI 10.1097/mpa.0000000000001652↗
  27. Endoscopic ultrasound-guided fiducial marker placement for neoadjuvant chemoradiation therapy for resectable pancreatic cancer. Co-author DOI 10.4251/wjgo.v12.i7.768↗
  28. Clinical Features and Prognosis of Patients With the Bone Metastasis of Pancreatic Cancer: A Single-Institutional Cohort Study. Co-author DOI 10.1097/mpa.0000000000001098↗
  29. Selective identification of somatic mutations in pancreatic cancer cells through a combination of next-generation sequencing of plasma DNA using molecular barc… Co-author DOI 10.1371/journal.pone.0192611↗
  30. Prospective small bowel mucosal assessment immediately after chemoradiotherapy of unresectable locally advanced pancreatic cancer using capsule endoscopy: a ca… First author DOI 10.20524/aog.2016.0063↗
  31. Duodenal Hemorrhage from Pancreatic Cancer Infiltration Controlled through Combination Therapy with Gemcitabine and S-1. Co-author DOI 10.1159/000364819↗

Closest collaborators

The 25 strongest of 58 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kazuyoshi Ohkawa · 28 shared papers, 2018–2026 · strength 4.64
  2. Kenji Ikezawa · 25 shared papers, 2020–2026 · strength 4.36
  3. Yugo Kai · 20 shared papers, 2021–2026 · strength 3.65
  4. Makiko Urabe · 17 shared papers, 2021–2026 · strength 3.25
  5. Takuo Yamai · 17 shared papers, 2014–2026 · strength 2.45
  6. Hidenori Takahashi · 10 shared papers, 2018–2026 · strength 1.52
  7. Nobuyasu Fukutake · 11 shared papers, 2014–2026 · strength 1.39
  8. Ko Watsuji · 7 shared papers, 2023–2026 · strength 1.34
  9. Yusuke Seiki · 7 shared papers, 2023–2026 · strength 1.34
  10. Reiko Ashida · 9 shared papers, 2014–2025 · strength 1.08
  11. Shigenori Nagata · 6 shared papers, 2021–2026 · strength 1.07
  12. Kana Hosokawa · 4 shared papers, 2025–2026 · strength 0.96
  13. Yasuharu Kawamoto · 6 shared papers, 2022–2024 · strength 0.92
  14. Kazuma Daiku · 6 shared papers, 2021–2022 · strength 0.79
  15. Hirofumi Akita · 5 shared papers, 2018–2026 · strength 0.77
  16. Takumi Kinomoto · 3 shared papers, 2025–2026 · strength 0.71
  17. Kazuhiro Katayama · 6 shared papers, 2018–2021 · strength 0.60
  18. Tatsuya Ioka · 6 shared papers, 2014–2023 · strength 0.60
  19. Yoji Kukita · 4 shared papers, 2018–2026 · strength 0.59
  20. Teruki Teshima · 4 shared papers, 2016–2025 · strength 0.51
  21. Shinichiro Hasegawa · 2 shared papers, 2022–2026 · strength 0.38
  22. Hisataka Ogawa · 2 shared papers, 2022–2026 · strength 0.38
  23. Tomoya Ekawa · 2 shared papers, 2022–2026 · strength 0.38
  24. Hideaki Tahara · 2 shared papers, 2022–2026 · strength 0.38
  25. Kunihito Gotoh · 2 shared papers, 2023–2026 · strength 0.36

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.